SCHAFFHAUSEN, Switzerland
August 6, 2008

Orqis(R)
International GmbH, a medical products company marketing devices to treat heart failure, announced first use of the Cancion(R) System on May 27 by Dr. Maria Frigerio and Dr. Fabrizio Oliva at Ospedale Niguarda Ca' Granda-Milano, Milano, Italy, as part of the hospital's objective to provide the latest medical technology to treat patients.

Dr. Frigerio and Dr. Oliva successfully treated a patient hospitalized with heart failure who was not responding to optimized medical management. Treatment with the Cancion System improved the patient's health to the point where the patient was successfully discharged home after being hospitalized for six months (since December 2007). Remarkably, he has
remained out of the hospital over 65 days for any heart failure-related
conditions.

The Cancion System enables aortic flow therapy which provides
physicians with a low-risk tool to improve cardiac performance and unload
the heart -- without touching the heart. The catheter-based, percutaneous
device addresses patients suffering from acute decompensated heart failure
by moving blood from an iliac artery to the descending aorta through the
use of an extracorporeal circulatory support. This proprietary therapy
uniquely bridges the treatment gap between medical management and more
invasive procedures -- without ever touching the heart.

"There has been very little progress in creating effective new
approaches for treating patients with heart failure," stated Dr. Frigerio.
She continued, "The Cancion System provides Ospedale Niguarda Ca'
Granda-Milano with the latest technology so we may provide the best care
for our patients."

Laura Eaton, R.N., Director, U.S. Sales, Orqis Medical stated, "Use of
the Cancion System in this patient demonstrates the compelling hemodynamic
benefit of aortic flow therapy." She continued, "The Cancion System
provides physicians with a viable new option to treat heart failure
patients from a course of decline to a course of improvement."

The Cancion System is distributed in Italy by NGC Medical spa
(http://www.ngc.it).

About Heart Failure

Heart failure is a condition in which the heart becomes weakened and
cannot pump blood efficiently. Heart failure is caused by coronary artery
disease, past myocardial infarctions, cardiomyopathy and other underlying
cardiovascular disorders, and it is characterized by shortness of breath,
functional impairment, and edema.

About Orqis International GmbH

Orqis is a privately held medical device company that develops and
sells minimally invasive devices that improve cardiac performance through
aortic flow therapy. Orqis devices uniquely bridge the treatment gap
between medical management and more invasive procedures without ever
touching the heart. The percutaneous Cancion System bears the CE mark of
conformity, and the implantable Exeleras(R) System is in development.

For more information on Orqis Medical, please visit http://www.orqis.ch

Note: Orqis(R), Cancion(R), and Exeleras(R) are registered trademarks
of Orqis Medical Corporation.